Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC). However, the clinical benefit of cetuximab as an EGFRtargeting drug is still controversial, partially due to the lack of effective means to identify suitable patients. | Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer